Abstract
Proposed budget cuts to the National Institutes of Health (NIH) by the current administration pose significant risk to academic and small biopharma drug discovery in the USA. Yet even in this challenging climate, there are viable strategies to ensure continued scientific progress. We highlight several approaches, including harnessing the power of artificial intelligence (AI), diversifying funding sources, accelerating commercialization and licensing, fostering new global collaborations, and strengthening public engagement in science.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1151-1154 |
| Number of pages | 4 |
| Journal | Trends in Pharmacological Sciences |
| Volume | 46 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2025 |
Keywords
- NIH funding
- academic drug discovery centers
- political constraints
- small biopharma drug discovery
ASJC Scopus subject areas
- Toxicology
- Pharmacology
Fingerprint
Dive into the research topics of 'Resilient pathways for drug discovery in challenging times'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS